skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All


Show More


Show More

Show More


Show More

Show More

58 Total results for product and free and sample content found

Generics Bulletin

Pfizer Reports 80% Biosimilars Growth In Q3

pfizer biosimilars growth

Pfizer has reported 80% growth in its global biosimilars business for the third quarter of 2020, on the back of recent oncology launches. Though the company’s sterile injectables saw a slight drop in business, Pfizer’s biopharma business saw 4% growth.

Topic Coronavirus Biosimilars Deals

Pink Sheet

Germany Sets Direction Of Travel With New Biosimilar Guidelines

Biosimilars Germany

Germany is for the first time to adopt national guidelines on prescribing biologics and biosimilars in move towards increasing biosimilar uptake.

Topic EU Biosimilars

Chemist + Druggist Data

UK Sees PIP Codes Expand To Cover Hospital Drugs

Pharmacists PIP Code Expansion

Chemist + Druggist has expanded its “PIP code” system for UK pharmacy procurement to also encompass hospital drugs.

Topic BioPharmaceutical Regulation Biosimilars

Generics Bulletin

Top 50 Generics and Biosimilars Companies

Top 50 Companies Article Pack

The Annual Top 50 Generics & Biosimilars Companies League Table is here, and Generics Bulletin is sharing its content with you! Connect to league tables and commentary summarizing key developments for the Top 10 companies in generics and biosimilars, part of Generics Bulletin’s annual Top 50 ranking.

Topic Biosimilars

Datamonitor Healthcare

The evolving landscape of biosimilars

The evolving landscape of biosimilars

It is important to understand how the biosimilar market has developed over the past five years. Take a look at some of the key events here.

Topic Biosimilars

Generics Bulletin

Biosimilars Conference Coverage

Biosimilars Conference Coverage

Industry analysts from Generics Bulletin are bringing you free insights from their comprehensive biosimilars coverage. Obtain critical industry information covering new biosimilars launches, company strategies, and new biosimilars product development.

Topic Biosimilars


Scrip Preview Pharma Trends for 2020

Scrip Preview Pharma Trends for 2020

For Scrip’s annual preview, our journalists asked over 80 industry executives and experts for their predictions of the major trends for 2020. From AI to M&A, gene therapy to the upcoming US election, here’s what to watch for as we begin this  new decade.

Topic Biosimilars BioPharmaceutical

Generics Bulletin

Coherus Is Confident After US Ranibizumab Filing


Having seen its development partner Bioeq file with the FDA in December last year, Coherus is confident that it will be a leader in the US biosimilar ranibizumab market targeting Lucentis.

Topic Biosimilars Deal trends

Generics Bulletin

Alberta Is Second Canadian Province To Switch To Biosimilars


Alberta has become the second Canadian province to announce a biosimilar switching program, following the example set by British Columbia earlier this year. The move has been welcomed by Biosimilars Canada but criticized by originator-backed body Crohn’s and Colitis Canada.

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: